title: Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum.
abstract: Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53-year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.
authors: Department of Dermatology, York Teaching Hospital, York, UK. m.shareef@nhs.net
authors: M S
authors: MS
authors: Shareef
authors: L R
authors: LR
authors: Munro
authors: R G
authors: RG
authors: Owen
authors: A S
authors: AS
authors: Highet
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018450:Disease Progression; D006801:Humans; D006942:Hypergammaglobulinemia / Q000150:complications*; D007070:Immunoglobulin A; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000139:chemically induced* / Q000473:pathology; D011230:Precancerous Conditions / Q000473:pathology; D017511:Pyoderma Gangrenosum / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007070:Immunoglobulin A; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab